Misplaced Pages

Darbinurad

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2025)

Pharmaceutical compound
Darbinurad
Clinical data
Other namesD-0120
Identifiers
IUPAC name
  • 2-sulfanylmethyl]cyclopropyl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H16N2O2S
Molar mass324.40 g·mol
3D model (JSmol)
SMILES
  • C1CC1(CC(=O)O)CSC2=C(C=NC=C2)C3=CC=C(C=C3)C#N
InChI
  • InChI=InChI=1S/C18H16N2O2S/c19-10-13-1-3-14(4-2-13)15-11-20-8-5-16(15)23-12-18(6-7-18)9-17(21)22/h1-5,8,11H,6-7,9,12H2,(H,21,22)
  • Key:RHASGUGQMCVYMQ-UHFFFAOYSA-N

Darbinurad is a investigational new drug that is being evaluated for the treatment of gout. It is a selective urate transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations.

References

  1. Kaufmann D, Chaiyakunapruk N, Schlesinger N (November 2024). "Optimizing gout treatment: A comprehensive review of current and emerging uricosurics". Joint Bone Spine. 92 (2): 105826. doi:10.1016/j.jbspin.2024.105826. PMID 39622367.
  2. "Darbinurad". PatSnap.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: